There is a strong association between 25-hydroxyvitamin D (25[OH]D) deficiency (<50 nmol/L) and increased mortality, particularly for diabetes-related deaths.
For patients with heart failure and reduced ejection fraction, dapagliflozin is associated with a lower risk for worsening heart failure or death from cardiovascular causes, regardless of the presence of type 2 diabetes.
Treatment with linagliptin compared with glimepiride results in a noninferior risk for cardiovascular morbidity and mortality in patients with type 2 diabetes.
Treatment with metformin vs sulfonylureas is associated with a reduced risk for major adverse cardiovascular events among patients with type 2 diabetes and reduced kidney function.
Daily liraglutide, in addition to metformin and insulin, reduces HbA1c and improves glycemic control in young patients with type 2 diabetes.
Cardiorenal disease is commonly the first cardiovascular disease manifestation in patients with type 2 diabetes.
Researchers at EASD 2019 presented current data and ongoing clinical trial designs for the first-in-class experimental drug, imeglimin, for the treatment of type 2 diabetes.
ADO09, a coformulation of amylin analog pramlintide and A21G human insulin, is superior to insulin lispro for reducing postprandial blood glucose in patients with type 1 diabetes.
Positive phase 3 efficacy and safety data were announced at EASD 2019 for a novel glucagon-like peptide-1 receptor agonist, polyethylene glycol loxenatide (PED168).
Fatty liver index is a useful and simple clinical biomarker to identify individuals at risk of developing type 2 diabetes.
Researchers investigated the effects of canagliflozin on serum urate levels and gout in patients with type 2 diabetes.